Since its release in 2018, the film ‘Dying to Survive’ has sparked widespread public attention for its realistic portrayal of the struggles faced by cancer patients unable to afford expensive medications. The protagonist Cheng Yong is based on Lu Yong, a real-life chronic myeloid leukemia patient who became known for helping fellow patients access affordable generic drugs from India. Recently, updates about Lu Yong’s current life have reignited public interest. According to public reports, after being investigated by police years ago, Lu was ultimately cleared of criminal charges by prosecutors who determined his actions were not illegal. Since then, he has returned to a quiet life, running his textile export business while actively engaging in charitable work, particularly advocating for better access to rare disease treatments and reforms in China’s medical insurance policies. Lu has repeatedly emphasized that public focus should remain on patients’ struggles rather than on his personal story. Today, the social impact of ‘Dying to Survive’ continues, with the Chinese government implementing measures to lower cancer drug prices, accelerate approval of generics, and include key medications in the national insurance coverage. Lu Yong’s journey stands not only as a tale of individual courage but also as a catalyst for meaningful pharmaceutical policy reform in China.
电影《我不是药神》自2018年上映以来，因其对高价抗癌药与患者生存困境的真实刻画引发广泛社会关注。影片主角程勇的原型人物——陆勇，是一位慢性粒细胞白血病患者，也是早期通过印度代购仿制药帮助病友的民间英雄。近日，有关陆勇现状的报道再次引发公众热议。据公开信息显示，陆勇在经历当年被警方立案调查后，最终因检方认定其行为不构成犯罪而获释。此后他回归正常生活，继续从事纺织品出口生意，并积极参与公益事业，致力于推动罕见病药物可及性与医保政策改革。他本人多次表示，希望社会能更多关注患者群体的用药困境，而非聚焦于他个人。如今，《我不是药神》带来的社会影响仍在持续，国家也陆续出台多项政策降低抗癌药价格、加快仿制药审批，部分药品已纳入医保目录。陆勇的故事不仅是一段个体抗争史，更成为中国医药制度改革的重要推动力之一。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/4600.html